Apitope appoints Dr Geoffrey Vernon chairman
This article was originally published in Scrip
Apitope International (Belgium), a developer of peptide-based therapies for autoimmune diseases and allergy, has named Dr Geoffrey Vernon chairman. He succeeds Richard Daniels, who continues as a non-executive director. Dr Vernon has more than 30 years' experience in healthcare through the UK's national health service and companies including Ciba-Geigy Pharmaceuticals, Schering Chemicals and Travenol Laboratories.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.